Temple University Gastroparesis Clinical Center

天普大学胃轻瘫临床中心

• 批准号: 9357609
• 负责人: HENRY PAUL PARKMAN
• 金额: $ 36.15万
• 依托单位: TEMPLE UNIV OF THE COMMONWEALTH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-15 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9357609
• 关键词: Abdominal Pain; Agonist; Applications Grants; Area; Biological Markers; Biopsy; Biopsy Specimen; Buspirone; Chronic; Clinical; Clinical Data; Clinical Research; Comorbidity; Diagnosis; Disease; Etiology; Evaluation; Fibrosis; Freezing; Functional disorder; Gastric Emptying; Gastroparesis; Genetic Transcription; Goals; Grant; Histologic; Impairment; Investigation; Location; Maintenance; Malnutrition; Measures; Minority; Multicenter Studies; National Institute of Diabetes and Digestive and Kidney Diseases; Natural History; Nausea and Vomiting; Outcome; Pathogenesis; Pathologic; Pathology; Patient-Focused Outcomes; Patients; Periodicity; Physicians; Physiological; Predictive Factor; Prevalence; Pyloric antrum; Quality of life; Questionnaires; Recruitment Activity; Registries; Research; Sampling; Serotonin; Severities; Site; Specimen; Stomach; Symptoms; Techniques; Testing; Thick; Tissue Sample; Tissues; United States National Institutes of Health; Universities; Visit; cellular pathology; chronic pancreatitis; diabetic; early satiety; effective therapy; follow-up; gastrointestinal symptom; improved; improved outcome; insight; interest; motility disorder; multidisciplinary; novel; patient population; programs; receptor; repository; response; symptom treatment; targeted treatment; transcriptome sequencing; transcriptomics; treatment response; treatment strategy

PROJECT SUMMARY Patients with gastroparesis often suffer with chronic gastrointestinal symptoms that are not adequately treated due to both a lack of understanding of the underlying pathophysiology and lack of effective treatments. The participation of Temple University as a clinical center in the NIDDK Gastroparesis Clinical Research Consortium and the proposed studies will help achieve the broad, long term objectives of improving the understanding and treatment of patients with gastroparesis. The PI and Temple University are well qualified to continue to be one of the clinical centers in this consortium. Temple University has clinical expertise and an active research program in the evaluation and treatment of patients with gastroparesis. The aims for this renewal of the Gastroparesis Consortium are threefold. First, to better understand the pathologic basis of gastroparesis by continuing to provide gastric full thickness biopsy specimens from patients with gastroparesis. We are now collecting specimens from the antrum and obtaining freshly frozen tissue for RNA expression. Second, to better understand the clinical manifestations and pathophysiology of patients with symptoms of gastroparesis by maintaining and expanding the Gastroparesis Registry. Our goal is to have four years of follow-up on patients which will require maintenance of the Registry and continued periodic follow-up visits. We propose to continue recruitment of new patients. Refinements to existing questionnaires and pathophysiologic measures, as well as new ones, will allow us to answer questions related to the pathogenesis, severity grading, complications, treatment responses, and clinical outcomes in patients with gastroparesis. Third, to conduct new multicenter studies of gastroparesis investigating the pathophysiology, diagnosis, and treatment. Our application proposes three studies, each aimed at the understanding of the pathophysiology of symptoms and treatment of symptoms from gastroparesis. Improved testing will better associate pathophysiology with gastroparesis symptoms and ultimately enable targeted therapy to the underlying gastric pathophysiologic abnormality. Our first study will determine the effect of the 5HT-1 receptor agonist, buspirone, on early satiety and intragastric meal distribution in patients with symptoms of gastroparesis. Our second study is an evaluation of abdominal pain in gastroparesis, determining the prevalence of and response to treatment for chronic pancreatitis. Finally, our third study will assess the clinical outcome of patients undergoing endoscopic pyloromyotomy for gastroparesis, looking at the response and predictive factors for clinical improvement with this novel treatment. These three studies will ultimately enable physicians to better target therapy to the underlying pathophysiologic abnormalities in patients with gastroparesis. Temple's participation in the NIH Gastroparesis Clinical Consortium and the undertaking of Temple's proposed studies will help achieve the goal of the consortium by advancing our understanding of the pathophysiology and developing appropriate treatments for patients with symptomatic gastroparesis.

项目摘要 胃轻瘫患者经常患有慢性胃肠道症状，没有得到充分的治疗 这是由于对潜在的病理生理学缺乏了解和缺乏有效的治疗。的 天普大学作为临床中心参与NIDDK胃轻瘫临床研究 联合会和拟议的研究将有助于实现改善 了解和治疗胃轻瘫患者。PI和天普大学完全有资格 继续成为该联盟的临床中心之一。天普大学拥有临床专业知识和 积极的研究计划，在评估和治疗胃轻瘫患者。其目的是 胃轻瘫联盟的更新有三个方面。首先，为了更好地了解 通过继续提供来自胃轻瘫患者的胃全层活检标本， 我们现在正在收集胃窦标本，并获得新鲜冷冻的组织用于RNA表达。 其次，更好地了解患者的临床表现和病理生理症状， 通过维持和扩大胃轻瘫登记处来治疗胃轻瘫。我们的目标是在四年内 对需要维持登记研究和持续定期随访的患者进行随访。 我们建议继续招募新患者。对现有调查表的改进， 病理生理措施，以及新的，将使我们能够回答有关的问题， 发病机制、严重程度分级、并发症、治疗反应和临床结局 胃轻瘫第三，进行新的多中心胃轻瘫研究，调查病理生理学， 诊断和治疗。我们的申请提出了三项研究，每项研究都旨在了解 症状的病理生理学和胃轻瘫症状的治疗。改进的测试将更好地 将病理生理学与胃轻瘫症状相关联，并最终实现对胃轻瘫患者的靶向治疗。 潜在的胃病理生理异常。我们的第一项研究将确定5 HT-1受体的作用， 激动剂丁螺环酮对有症状的患者的早饱感和胃内膳食分布的影响 胃轻瘫我们的第二项研究是评估胃轻瘫患者的腹痛， 慢性胰腺炎的患病率和对治疗的反应。最后，我们的第三项研究将评估临床 接受内镜幽门肌切开术治疗胃轻瘫的患者的结局，观察反应， 这种新型治疗的临床改善的预测因素。这三项研究最终将使 医生更好地针对患者的潜在病理生理异常进行治疗， 胃轻瘫坦普尔参与了NIH胃轻瘫临床联盟， 坦普尔提出的研究将有助于实现该联盟的目标， 病理生理学和开发适当的治疗有症状的胃轻瘫患者。